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Introduction
Multiple myeloma (MM) is a malignancy characterized by an accumulation of clonal plasma cells (1) (2) (3) . Current therapies for MM often cause remissions, but nearly all patients eventually relapse and die (1, 2) . There is substantial evidence of an immunemediated elimination of myeloma cells in the setting of allogeneic hematopoietic stem There is clearly a great need for new immunotherapies for MM, and developing an effective antigen-specific adoptive T-cell therapy for this disease would be a major advance.
Adoptive transfer of T cells genetically modified to recognize malignancy-associated antigens is a promising approach for cancer therapy (8, 9) . T cells can be genetically modified to express chimeric antigen receptors (CARs), which are fusion proteins that include an antigen recognition moiety and T cell activation domains (9, 10) . For Blineage malignancies, substantial progress has been made recently in developing adoptive T cell approaches that utilize anti-CD19 CARs (11) (12) (13) (14) (15) (16) (17) (18) . Anti-CD19-CARtransduced T cells have cured leukemia and lymphoma in mice (19, 20) . Several patients obtained remissions in early clinical trials of adoptively transferred anti-CD19-CAR-transduced T cells, and T cells transduced with anti-CD19 CARs also eradicated normal B cells (12, 13, 17, 21) . Unfortunately, CD19 is rarely expressed on the malignant plasma cells of MM, so treating MM with CAR-expressing T cells will require identifying other antigens to target (22, 23) .
One candidate antigen for immunotherapies of MM is B-cell maturation antigen (BCMA, CD269) (24, 25) . BCMA RNA was detected universally in MM cells, and BCMA protein was detected on the surface of plasma cells from multiple myeloma patients by several investigators (26) (27) (28) (29) . BCMA is a member of the tumor necrosis factor receptor (TNF) superfamily (30, 31) . BCMA binds B-cell activating factor (BAFF) and a proliferation inducing ligand (APRIL) (31) (32) (33) . Among nonmalignant cells, BCMA has been reported to be expressed mostly by plasma cells and subsets of mature B cells (24, 25, 32, 34, 35) . Mice deficient in BCMA were healthy and had a normal physical appearance (36, 37) . BCMA-deficient mice had normal numbers of B cells, but survival of long-lived plasma cells was impaired (34, 36) .
We reasoned that BCMA would be an appropriate target antigen for treating MM with CAR-expressing T cells. Except for expression on plasma cells, we found that BCMA is not expressed on the cells of major human organs. We designed lentiviral vectors that encoded BCMA-specific CARs. T cells transduced with these vectors performed BCMA-specific functions including cytokine production, proliferation, and cytotoxicity.
Materials and Methods

Cell lines and primary cells
H929, U266, and RPMI8226 are all BCMA + multiple myeloma cell lines that were obtained from ATCC. A549 is a BCMA-negative lung cancer cell line (ATCC). TC71 is a BCMA-negative sarcoma cell line. CCRF-CEM is a BCMA-negative T cell line (ATCC). BCMA-K562 are K562 cells (ATCC) transduced with the gene for full-length BCMA in our laboratory. NGFR-K562 are K562 cells transduced with the gene for lowaffinity nerve growth factor in our laboratory (38) . The same gammaretroviral vector and methods were used to transduce BCMA-K562 and NGFR-K562. We used tissue 
Real-time qPCR to quantitate BCMA transcript copies
We quantitated BCMA cDNA copies in samples of cDNA from human tissues included in the Human Major Tissue qPCR panel II (Origene) by performing qPCR with a BCMAspecific primer and probe set (Applied Biosystems, catalog number 4331182). As a positive control, we quantitated BCMA cDNA copies in cDNA of MM cells from a plasmacytoma of a patient with advanced multiple myeloma. RNA was extracted from the plasmacytoma cells with an RNeasy mini kit (Qiagen), and cDNA was synthesized with standard methods. A standard curve for the BCMA qPCR was created by amplifying dilutions of a plasmid that encoded the full-length cDNA of BCMA (Origene).
The qPCR accurately detected copy numbers from 10 2 to 10 9 copies of BCMA per reaction. We also quantitated the number of β-actin cDNA copies in the same tissues with a Taqman β-actin primer and probe kit (Applied Biosystems). A β-actin standard curve was created by amplifying serial dilutions of a β-actin plasmid. All qPCR reactions were carried out on a Roche LightCycler480 machine.
Immunohistochemistry
Research. BCMA stains were performed on formalin-fixed paraffin-embedded tissue sections and on a commerical normal human tissue array (Pantomics Inc. catalog number MN0661).
NGFR-K562 cells (BCMA-negative), BCMA-K562 cells (BCMA-positive) and sections from reactive tonsils were used as controls. Sections were deparaffinized in xylene, rehydrated in graded-alcohol, placed in 1X low pH antigen retrieval solution (Dako, catalog number S1699), and steamed for 30 minutes. Sections were blocked with Dako protein-block-serum-free (catalog number X0909) for 30 minutes, and blocked with 5% bovine serum albumin (Sigma-Aldrich) for another 30 minutes. The sections were then incubated for 60 minutes at room temperature (RT) with either 1µg/mL anti-BCMA goat polyclonal antibody (R&D Systems, catalog number AF193) or with an isotype control of 1µg/mL normal purified goat IgG. Biotinylated rabbit anti-goat IgG was used as the secondary antibody (Vector Lab, catalog number BA-5000; 7.5 µg/mL, 30 minute incubation, RT). Vectastain ABC Kit (Vector Lab, catalog number PK4005; 30 minute incubation, RT) and DAB+Chromogen (Dako, catalog number K4011; 5 minute incubation, RT) were used for detection. For BCMA and MUM1 double staining, BCMA stained sections were re-retrieved in hot Dako 1X low pH antigen retrieval solution and microwaved for 6 min. Sections were blocked with Dako protein-block-serum-free for 30 min, incubated with MUM1 mouse monoclonal antibody ( Dako, M7259; 1:100 dilution, 120 min incubation, RT) and detected with Ventana BenchMark XT with Ventana ultraView universal alkaline phosphatase red detection kit (AZ, 760-501).
Images were taken with an Olympus Bx41 microscope: objective UPlanFI 100x/1.30 oil, adaptor U-TV0.5xC, digital camera Q-imaging Micropublisher 5.0 RTV. The images were captured with "Q-Capture Version 3.1" and imported to Adobe Photoshop 7.0.
Research. 
Construction of anti-BCMA chimeric antigen receptors (CARs)
Sequences of 2 mouse-anti-human-BCMA antibodies were obtained from a patent (39) .
The specific antibodies used were designated in the patent as C12A3.2 and C11D5.3.
The heavy chain and light chain variable-region sequences of these antibodies were used to design single chain variable fragments (scFvs) with the following pattern: light chain variable region-linker-heavy chain variable region. The linker had the following amino acid sequence: GSTSGSGKPGSGEGSTKG (15) . CARs incorporating variable regions from C12A3.2 and C11D5.3 were designated anti-bcma1 and anti-bcma2 respectively. DNA sequences encoding these CARs were designed. The sequence of each CAR followed this pattern from the 5' end to the 3' end: the CD8α signal sequence, scFv, hinge and transmembrane regions of the human CD8α molecule, the cytoplasmic portion of the CD28 molecule, and the cytoplasmic portion of the CD3ζ molecule. The sequences used for CD8α, CD28, and CD3ζ were obtained from the National Center for Biotechnology Information website (www.ncbi.nlm.nih). Guidance regarding the portions of each molecule to include in the CARs was obtained from prior work (38) . DNA encoding the CARs was codon optimized and synthesized by GeneArt AG with appropriate restriction sites. The CAR sequences were ligated into a lentiviral vector plasmid designated pRRLSIN.cPPT.MSCV.coDMF5.oPRE (40) . The coDMF5 portion of this vector was replaced with the CAR sequences by using standard methods. constructed (10) . This CAR was referred to as SP6. The SP6 CAR was cloned into the same lentiviral vector as the anti-BCMA CARs and contained the same signaling domains as the anti-BCMA CARs.
Lentiviral Supernatant Production
Supernatant that contained lentiviruses encoding each CAR was produced by following a previously published protocol (40) . To produce the supernatant, 293T-17 cells (ATCC) were transfected with the following plasmids as detailed previously: pMDG (encoding the vesicular stomatitis virus envelope), pMDLg/pRRE (encoding gag and pol), pRSV-Rev (encoding Rev), and the appropriate CAR-encoding plasmid (40) .
T cell transductions
T cells were cultured as described previously (38) . In brief, PBMC were stimulated with the anti-CD3 monoclonal antibody OKT3 (Ortho) in AIM V medium (Invitrogen) containing 5% human AB serum (Valley Biomedical) and 300 international units (IU)/mL of interleukin-2 (IL-2, Chiron). Thirty-six hours after the cultures were started, the activated PBMC were suspended in lentiviral supernatant with protamine sulfate and 300 IU/mL IL-2. The cells were centrifuged for 1 hour at 1200xg. The cells were then cultured for 3 hours at 37 °C. Next, the supernatant was diluted 1:1 with RPMI (Mediatech)+10% fetal bovine serum (Invitrogen) and IL-2. The cells were cultured in 
CAR detection on transduced T cells by anti-Fab antibody staining
T cells were stained with biotin-labeled polyclonal goat anti-mouse-F(ab) 2 antibodies (anti-Fab, Jackson Immunoresearch) to detect the anti-BCMA CARs as described previously (38) .
Flow cytometry
For anti-BCMA staining, cells were stained with polyclonal biotin-labeled goat-antihuman BCMA antibodies (R&D, catalog number BAF 193) followed by streptavidin (BD). Bone marrow cells were also stained with anti-CD38 (eBioscience) and anti-CD56 (BD). Flow cytometry analysis for all experiments was performed by using FlowJo (Tree Star, Inc.).
ELISA, CD107a, intracellular cytokine staining, and proliferation assays
These assays were performed by using standard methods as previously published (17, 38) . Details of the methods for these techniques are in the Supplemental Methods.
Cytotoxicity Assay
Cytotoxicity assays were conducted as previously described (38) After demonstrating a very restricted expression pattern of BCMA RNA, we carried out an assessment of BCMA protein expression by immunohistochemistry (IHC). As expected, our anti-BCMA IHC staining procedure yielded strong staining of BCMA-K562 cells and a lack of staining with NGFR-K562 negative control cells (Figures 2A abd 2B ).
We went on to evaluate BCMA protein expression in normal human organs. Except for plasma cells, we did not detect BCMA protein expression by the cells of any of the organs that we stained. We detected plasma cells expressing cell-surface BCMA in gastrointestinal organs. Examples of BCMA-expressing plasma cells that were detected in the stomach and rectum are shown in Figure 2C and 2D. MUM1 (multiple myeloma 1) is a protein that is expressed by many malignant and benign lymphocytes and by plasma cells (43) . Except for lymphocytes and plasma cells, MUM1 is not expressed by normal gastrointestinal tissues (43) . We performed IHC double staining of colon and duodenum with anti-BCMA and anti-MUM1and found that BCMA was expressed only by lymphoid cells and plasma cells ( Figure 2E ). BCMA expression by plasma cells probably accounts for the low levels of BCMA RNA detected in these organs because we did not detect BCMA expression by any of the other cells in these organs. We detected BCMA-expressing plasma cells in the tonsil (data not shown).
The organs assessed by IHC and found to lack BCMA expression except for plasma cells included the following: adrenal, bladder, bone, eye, breast, cerebellum, cerebral cortex, fallopian tube, esophagus, stomach, small intestine, colon, rectum, heart, kidney, liver, lung, ovary, pancreas, parathyroid, pituitary, placenta, prostate, skin, spinal cord, spleen, skeletal muscle, testis, thymus, thyroid, trachea, cervix, uterine endometrium.
Research. Figure 2F-H) . These sections are shown in Figure 2 . In all 3 of the samples, the neoplastic plasma cells expressed cell-surface BCMA.
BCMA-specific CARs were expressed on transduced T cells
BCMA is expressed on multiple myeloma cells, and it has a restricted expression pattern in normal tissues ( Figure 1 and Figure 2 ). Due to the expression pattern of BCMA, we reasoned that BCMA would be an appropriate target for CAR-expressing T cells. To further assess the suitability of BCMA as a target for CAR-expressing T cells, we designed two CARs. Each CAR contained an scFv derived from one of two mouse anti-human-BCMA monoclonal antibodies (39) . We named the two CARs anti-bcma1 and anti-bcma2. The CARs contained the hinge and transmembrane regions of the human CD8α molecule, the signaling moiety of the CD28 costimulatory molecule, and the signaling domains of the CD3ζ molecule ( Figure 3A) . We also designed a negativecontrol CAR named SP6. The SP6 CAR contained the variable regions of the haptenspecific SP6 monoclonal antibody (10) . Except for the different variable regions, the sequence of the SP6 CAR was identical to the sequences of anti-bcma1 and antibcma2. We ligated DNA encoding each of the CARs that we designed into a selfinactivating lentiviral vector, which has been described in detail previously (40) .
Replication-incompetent lentiviruses encoding the CARs were used to transduce human 
T cells. After transductions, we found high levels of cell surface expression of antibcma1, anti-bcma2, and SP6 on the transduced T cells ( Figure 3B ).
Anti-BCMA-CAR-transduced T cells degranulated and produced cytokines specifically in response to BCMA-expressing target cells
Anti-BCMA-CAR-transduced T cells upregulated CD107a specifically in response to stimulation with BCMA-expressing target cells ( Figure 3C ). This indicates BCMAspecific degranulation of the T cells, which is a requirement for perforin-mediated cytotoxicity (44) .
We assessed the ability of anti-BCMA-CAR-transduced T cells to produce cytokines in response to BCMA. T cells transduced with either anti-bcma1 or anti-bcma2 produced large amounts of IFNγ when they were cultured overnight with the BCMAexpressing target cell line BCMA-K562, but the CAR-transduced T cells only produced background levels of IFNγ when they were cultured with the negative-control target cell line NGFR-K562 (Table 1) 
Anti-BCMA-CAR-transduced T cells proliferated in response to BCMA
We assessed anti-bcma2-transduced T cells for the ability to proliferate when stimulated with BCMA-expressing target cells. We cultured CFSE-labeled, anti-bcma2-transduced T cells with either target cells that expressed BCMA or target cells that did not express BCMA ( Figure 4B ). Anti-bcma2-transduced T cells specifically proliferated when stimulated with BCMA-expressing target cells. As expected, there was no BCMAspecific proliferation when T cells transduced with the SP6 negative-control CAR were assessed. At the beginning of the proliferation assay reported in Figure 4B , 0.8x10 cells were present in the cultures containing NGFR-K562 cells. This BCMA-specific increase in the absolute number of anti-bcma2-expressing T cells confirms the results of the CFSE proliferation assay.
Anti-BCMA-CAR-transduced T cells killed multiple myeloma cell lines.
T cells transduced with anti-bcma2 specifically killed the BCMA-expressing multiple myeloma cell lines H929 and RPMI8226 in 4-hour cytotoxicity assays ( Figures 4C and   4D ). SP6-transduced T cells exhibited much lower levels of cytotoxicity against these cell lines.
Anti-BCMA-CAR-transduced T cells eradicate tumors in vivo.
We established RPMI8226 human multiple myeloma cell line tumors in immunodeficient mice. We allowed sizable tumors to develop over 17 to 19 days, and then we treated the mice with a single intravenous infusion of anti-bcma2-transduced human T cells. Figure 5F ).
Discussion
Because current therapies for MM are rarely curative, new therapies for this disease are clearly needed (1, 2) . In particular, there is a need for therapies to eradicate residual malignant cells that persist in patients who obtain remissions with current treatments.
Many monoclonal antibodies that could potentially be useful therapies for MM are currently being evaluated in clinical trials, but most of these antibodies target antigens (26) (27) (28) . In early studies, BCMA RNA was detected in a limited number of normal tissues (24, 25) . BCMA RNA was not expressed by normal human T cells or myeloid cells (35) . BCMA has been reported to be expressed by fibroblast-like synovial cells from patients with the autoimmune disease rheumatoid arthritis, but BCMA was not expressed by synovial cells from patients with osteoarthritis (49). BCMA mRNA has been previously detected in the gut-associated lymphoid tissues, which are known to contain B cells and plasma cells (41, 50) . We measured BCMA transcript expression in a wide range of normal tissues and found that BCMA mRNA expression was quite limited ( Figure 1B) . We also determined that BCMA was not expressed on the cell surfaces of primary CD34 + hematopoietic cells ( Figure 1A ). 
of both of these patients killed BCMA-expressing target cells in vitro by complementmediated lysis and antibody-dependent cellular cytotoxicity (28).
In conclusion, BCMA is a promising target for CAR-transduced T cells. We have presented evidence that BCMA is not expressed by normal essential cells, and we 
